Anaptys Partner Search Boosted By Phase III Skin Disease Success

After disappointments in other indications, notably hidradenitis suppurativa, AnaptysBio has posted positive Phase III results for its IL-36 receptor-targeting monoclonal antibody imsidolimab in generalized pustular psoriasis.

Daniel Faga
CEO Daniel Faga • Source: AnaptysBio

AnaptysBio, Inc. has suffered a series of setbacks in the clinic with imsidolimab but its success in a late-stage trial for a rare but potentially life-threatening form of psoriasis could, it hopes, lead to a lucrative licensing deal. 

Key Takeaways
  • AnaptysBio's imsidolimab will be filed next year for generalized pustular psoriasis

The San Diego, CA-based firm has unveiled positive topline data from the Phase III GEMINI-1 trial evaluating imsidolimab in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

More from Therapy Areas

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.